ART Advanced Research Technologies to Present Molecular Imaging Applications at AACR Meeting in Denver
April 17 2009 - 8:22AM
Marketwired
ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a
Canadian medical device company and a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries,
will be exhibiting at the Annual Meeting of the American
Association for Cancer Research (AACR), April 19-22, in Denver,
Colorado. ART will showcase its preclinical product offering,
including current research in oncology and related fields using the
Optix� optical imaging device, as well as the Fenestra� line of
contrast agents for microCT imaging, at its booth (#757) located in
the Colorado Convention Center.
The Annual Meeting of the American Association for Cancer
Research (AACR) is the world's largest and most comprehensive
gathering of professionals in the cancer field, encompassing basic,
translational, and clinical research. This prestigious annual event
highlights the latest developments in cancer research and is
attended by over 17,000 delegates from universities, research
institutions and the pharmaceutical industry.
About the Optix� system
Based on time-domain technology, which allows measurement of the
light's time of arrival, the Optix� in vivo optical molecular
imaging device is the most sensitive optical imager commercially
available on the preclinical market, allowing for detection of
lower concentrations of signals deeper inside the body. Unique to
the Optix system is the ability to recover fluorescence lifetime,
which can be used to separate and quantify probe distributions
depending on their respective biochemical environment. Also part of
the Optix product offering is a CT fusion software package allowing
researchers to export the scan obtained using Optix in DICOM
format, and fuse it with microCT for a full 3D anatomical
reference.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra�
line of molecular imaging contrast products provides image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART
is commercializing some of these products in a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2008, available on SEDAR (www.sedar.com).
Contacts: ART ADVANCED RESEARCH TECHNOLOGIES INC. Jacques Bedard
Chief Financial Officer jbedard@art.ca www.art.ca ART ADVANCED
RESEARCH TECHNOLOGIES INC. Dino DiCamillo Vice President, Global
Sales and Marketing, Preclinical Research 514-832-0777
ddicamil@art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024